Beyond Mega-Caps: Antimicrobial Patents and Tanker Surges Signal Small-Cap ShiftGlobal Report·Oct 7, 2026 at 10:13 AMASTH+0.38%TNK+0.87%
Instinct Bio named CelSiege representative for IN01 cancer immunotherapy in Japan, ChinaPUBT·Oct 1, 2026 at 10:08 AMBIOT+2.68%
Rolling NDA Submissions Reshape Biotech Development PlaybookGlobal Report·Sep 30, 2026 at 10:13 AMBIOT+2.68%BLFS0.00%
Weekly Recap | BIOT.US +21.05%, a high-volume push toward recent highsWeekly Review·Sep 19, 2026 at 05:43 AMBIOT+2.68%
The 2026 Biotech Identity Crisis: Subscriptions, SPACs, and the AI PivotGlobal Report·Sep 18, 2026 at 10:15 AMBIOT+2.68%LABT-1.98%
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives | BIOT Stock NewsStockTitan·Sep 4, 2026 at 03:00 AMBIOT+2.68%
Instinct Bio partners with Indonesia’s Parva Candela to expand cosmetics businessPUBT·Aug 10, 2026 at 11:05 AMBIOT+2.68%
BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets | BIOT Stock NewsStockTitan·Jul 29, 2026 at 06:28 AMBIOT+2.68%
Instinct Bio Stock Slides After Hours: Here's What is Going on With BIOTbenzinga_article·Jul 29, 2026 at 05:37 AMBIOT+2.68%
Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth | ACQC Stock NewsStockTitan·Jul 28, 2026 at 06:01 AMBIOT+2.68%
